Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
KSE - Delayed Quote KRW

GC Biopharma Corp. (006280.KS)

Compare
117,600.00
-7,600.00
(-6.07%)
At close: 3:30:30 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,679,891,941.47
1,679,891,941.47
1,626,643,815.82
1,711,312,739.53
1,537,825,750.25
Cost of Revenue
1,197,959,660.98
1,197,959,660.98
1,142,011,052.95
1,129,508,276.27
1,017,232,478.29
Gross Profit
481,932,280.49
481,932,280.49
484,632,762.87
581,804,463.26
520,593,271.96
Operating Expense
449,824,933
449,824,933
450,191,593
500,540,797
446,857,651
Operating Income
32,107,347.49
32,107,347.49
34,441,169.87
81,263,666.26
73,735,620.96
Net Non Operating Interest Income Expense
-37,846,236.86
-37,846,236.86
-25,293,186.20
-14,925,690.98
-11,236,240.21
Pretax Income
-41,109,728.85
-41,109,728.85
-27,134,762.73
85,727,859.93
172,559,285.89
Tax Provision
1,527,335.66
1,527,335.66
-7,326,031.75
16,313,075.34
35,609,406.65
Net Income Common Stockholders
-26,280,215.15
-26,280,215.15
-26,631,783.14
65,453,133.85
123,211,805.90
Basic EPS
-2.30k
--
-2.33k
5.74k
10.80k
Diluted EPS
-2.30k
--
-2.33k
5.74k
10.80k
Basic Average Shares
11,411.30
--
11,415.25
11,412.93
11,412.73
Diluted Average Shares
11,411.30
--
11,415.25
11,412.93
11,412.73
Total Operating Income as Reported
32,107,347.88
32,107,347.88
34,436,169.53
81,263,665.84
73,661,620.77
Rent Expense Supplemental
4,789,000
4,789,000
4,279,000
4,023,000
3,276,000
Total Expenses
1,647,784,593.98
1,647,784,593.98
1,592,202,645.95
1,630,049,073.27
1,464,090,129.29
Net Income from Continuing & Discontinued Operation
-26,280,215.15
-26,280,215.15
-26,631,783.14
65,453,133.85
123,211,805.90
Normalized Income
-13,359,429.31
-13,359,429.31
-24,788,013.26
68,790,762.27
116,344,442.61
Interest Income
3,331,000
3,331,000
3,190,000
3,467,000
1,265,000
Interest Expense
40,439,237
40,439,237
28,483,187
18,392,691
12,501,240
Net Interest Income
-37,846,236.86
-37,846,236.86
-25,293,186.20
-14,925,690.98
-11,236,240.21
EBIT
-670,491.85
-670,491.85
1,348,424.27
104,120,550.93
185,060,525.89
EBITDA
80,363,675.15
80,363,675.15
77,247,424.27
169,216,550.93
240,964,525.89
Reconciled Cost of Revenue
1,197,959,660.98
1,197,959,660.98
1,142,011,052.95
1,129,508,276.27
1,017,232,478.29
Reconciled Depreciation
81,034,167
81,034,167
75,899,000
65,096,000
55,904,000
Net Income from Continuing Operation Net Minority Interest
-26,280,215.15
-26,280,215.15
-26,631,783.14
65,453,133.85
123,211,805.90
Total Unusual Items Excluding Goodwill
-17,001,034
-17,001,034
-2,525,667
-4,122,000
8,653,000
Total Unusual Items
-17,001,034
-17,001,034
-2,525,667
-4,122,000
8,653,000
Normalized EBITDA
97,364,709.15
97,364,709.15
79,773,091.27
173,338,550.93
232,311,525.89
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-4,080,248.16
-4,080,248.16
-681,897.12
-784,371.58
1,785,636.71
12/31/2021 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade